We're Lowering Our Price Target on Bristol Myers as Two Key Overhangs Persist

We're lowering our price target on Bristol Myers as two key overhangs persist

Shares were down around 5% on Thursday afternoon despite a beat-and-raise quarter.

Bristol Myers raises revenue guidance for the year, prepares for major Cobenfy readouts

Bristol Myers Squibb is upping its revenue guidance for 2025 by $700 million. The pharma company said Thursday that it now expects to bring in between $46.5 billion and $47.5 billion ...